Clinical trials registries were searched to identify any additional studies investigating central nervous system (CNS) metastases in metastatic breast cancer, and are noted in the Cancer Australia systematic review.7 Areas of ongoing research in this population include:
- A phase II randomised controlled trial in Korea (NCT01622868) among patients with HER2-positive breast cancer, comparing patients taking lapatinib ditosylate and undergoing WBRT, with patients undergoing WBRT alone.133
- A French phase II randomised controlled trial (NCT00875355) on temozolomide use among patients having WBRT.134
- A phase II open-label study in the US (NCT00397501) comparing blood-brain barrier disruption followed by methotrexate and carboplatin, with or without trastuzumab.135
- A phase II randomised open-label study in France (NCT00977379) comparing capecitabine and WBRT with WBRT alone.136
- A US-based phase II open-label study (NCT01480583) comparing GRN1005 in combination with trastuzumab for HER2-positive patients with GRN1005 alone in HER2-negative patients.137
- A phase II, interventional open-label study in the US (NCT01494662) comparing 240mg daily of HKI-272/Neratinib to 40mg daily plus surgical resection.138
- A French phase III randomised controlled trial investigating the addition of concurrent prophylactic cranial radiotherapy to taxane/trastuzumab therapy.139
- A randomised phase III trial in the US (NCT01372774) comparing post-surgical SRS with post-surgical WBRT.140
- A phase II US-based trial (RTOG 0933) investigating hippocampal avoidance in WBRT.141
- A phase I randomised study on stereotactic radiosurgery to the cavity following surgical resection of brain metastases142